STOCK TITAN

Context Therapeutics Inc. - CNTX STOCK NEWS

Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.

Context Therapeutics Inc. (Nasdaq: CNTX) is a Philadelphia-based biopharmaceutical company dedicated to advancing innovative medicines for solid tumors. The company's core mission is to develop novel therapies for hormone-responsive cancers, with a particular focus on female cancers such as breast, ovarian, and endometrial cancer.

Context Therapeutics’ leading clinical candidate is CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target and engage T-cells in attacking CLDN6-positive tumors. Preclinical studies have shown promising results, with CTIM-76 demonstrating a capability to induce complete tumor regressions across multiple dose levels. The company plans to enroll the first patient in a Phase 1 clinical trial in mid-2024.

In addition to CTIM-76, Context Therapeutics is working on other promising programs, including Apristor (onapristone XR), an investigational drug targeting progesterone receptor-positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptors, making Apristor a potential treatment option for a significant number of patients.

In recent news, Context Therapeutics announced encouraging financial results for the first quarter of 2024, including gross proceeds of approximately $100 million from a private placement. These funds are expected to support the company's operations and research endeavors well into 2028. The U.S. Food and Drug Administration (FDA) has also recently cleared Context's Investigational New Drug (IND) application for CTIM-76, a crucial step toward initiating clinical trials.

Context Therapeutics has a strong pipeline and strategic partnerships, including collaborations with Integral Molecular, which supports the development of therapies targeting difficult protein targets. The company’s robust financial guidance and innovative approach position it for significant growth in the biopharmaceutical sector.

Rhea-AI Summary

Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance from the U.S. FDA and is expected to begin Phase 1 trials in Q1 2025. The antibody targets mesothelin, prevalent in cancers like ovarian, lung, and pancreatic. Context plans to use its existing cash reserves to fund the acquisition and initial clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
-
Rhea-AI Summary

Context Therapeutics Inc. reported on the FDA clearance of their IND application for a Phase 1 clinical trial of CTIM-76 and completed a $100 million financing round. They anticipate funding to last until 2028. The company showcased financial results for Q1 2024, emphasizing a decrease in R&D expenses and a net loss of $3.7 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
-
Rhea-AI Summary

Context Therapeutics received FDA clearance for its IND application for a Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, focusing on gynecologic and testicular cancers. The Company aims to enroll the first patient by mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.68%
Tags
Rhea-AI Summary

Context Therapeutics Inc. announced a $100 million private placement with healthcare investors to advance medicines for solid tumors. The financing will extend the cash runway into 2028. The private placement is expected to close on May 6, 2024, and includes the sale of approximately 64.5 million shares of common stock at $1.55 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.68%
Tags
none
-
Rhea-AI Summary
Context Therapeutics Inc. announced the submission of an Investigational New Drug (IND) application for CTIM-76 to the FDA, marking a crucial step towards a Phase 1 clinical trial for CLDN6-positive gynecologic and testicular cancers. The CEO highlighted the program's potential and the team's dedication to advancing the therapy swiftly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. announced financial results for 2023, with cash reserves of $14.4 million. The company plans to file an IND for CTIM-76 by March 2024, targeting CLDN6-positive tumors. Recent highlights include amending collaboration terms with Integral Molecular, presenting promising preclinical data, and upcoming participation in the Needham Virtual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
Rhea-AI Summary
Context Therapeutics Inc. (CNTX) announces Q3 2023 financial results, with $21.7 million in cash and cash equivalents. The company is on track to file an IND for CTIM-76 in late Q1 2024, supported by promising preclinical data presented at the SITC 38th Annual Meeting. CTIM-76 demonstrated broad therapeutic potential and differentiated product profile, positioning it as a strong candidate for addressing CLDN6-positive tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. announces encouraging preclinical data for CTIM-76, a Claudin 6 x CD3 T-cell engaging bispecific antibody. CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models. Benchmarking studies show CTIM-76's differentiated product profile. CTIM-76 IND filing on track for late Q1 2024. Data to be presented at SITC 38th Annual Meeting on November 3rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. will present a poster on its preclinical asset, CTIM-76, at the SITC 38th Annual Meeting. The poster will discuss the development of CTIM-76, a highly specific Claudin 6 bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
none
Rhea-AI Summary
Context Therapeutics Inc. announces financial results for Q2 2023 and provides updates on preclinical asset CTIM-76
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags

FAQ

What does Context Therapeutics Inc. do?

Context Therapeutics is a biopharmaceutical company focused on developing innovative therapies for hormone-responsive cancers, particularly targeting solid tumors.

What is CTIM-76?

CTIM-76 is a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to engage T-cells in targeting CLDN6-positive tumors. It is Context Therapeutics' leading clinical candidate.

What types of cancer is Context Therapeutics targeting with their therapies?

Context Therapeutics is targeting hormone-dependent cancers, including breast, ovarian, and endometrial cancers.

What recent milestones has Context Therapeutics achieved?

Recently, Context Therapeutics raised $100 million through a private placement and received FDA clearance for its IND application for CTIM-76, paving the way for a Phase 1 clinical trial.

When does Context Therapeutics plan to start the Phase 1 trial for CTIM-76?

The company plans to enroll the first patient in the Phase 1 clinical trial for CTIM-76 in mid-2024.

What are the financial prospects for Context Therapeutics?

The company expects that its current cash and cash equivalents, along with recent funding, will sustain its operations into 2028.

Who are some of Context Therapeutics' strategic partners?

Context Therapeutics collaborates with Integral Molecular, a leader in developing technologies for therapeutic discovery against difficult protein targets.

What regulatory approvals has Context Therapeutics received recently?

The FDA has cleared Context Therapeutics' IND application for CTIM-76, supporting the initiation of a Phase 1 clinical trial.

Where is Context Therapeutics headquartered?

Context Therapeutics is headquartered in Philadelphia, Pennsylvania.

What is Apristor?

Apristor (onapristone XR) is an investigational drug developed by Context Therapeutics for treating progesterone receptor-positive (PR+) breast cancer.

Context Therapeutics Inc.

Nasdaq:CNTX

CNTX Rankings

CNTX Stock Data

151.50M
75.00M
2.78%
46.95%
1.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA